Skip to main content
. 2019 May 10;20(9):2314. doi: 10.3390/ijms20092314

Figure 5.

Figure 5

Effect of pioglitazone on the proliferation of CKD-MSCs via the level of PrPC. (A) 5-bromo-2′-deoxyuridine (BrdU) assay in healthy-MSCs and CKD-MSCs after treatment with Pio. and si-PRNP. Values represent the mean ± SEM. ** p < 0.01 versus healthy-MSCs, ## p < 0.01 versus non-treated CKD-MSCs, $$ p < 0.01 versus pioglitazone-treated CKD-MSCs pretreated with si-PRNP; (B) The percentage of S phase in healthy-MSCs and CKD-MSCs after treatment with pioglitazone and si-PRNP. Values represent the mean ± SEM. * p < 0.05 versus healthy-MSCs, # p < 0.05 versus non-treated CKD-MSCs, $ p < 0.05 versus pioglitazone-treated CKD-MSCs, & p < 0.05 versus pioglitazone-treated CKD-MSCs pretreated with si-PRNP; (C) Activity of CDK4 in healthy-MSCs and CKD-MSCs after treatment with pioglitazone and si-PRNP. Values represent the mean ± SEM. ** p < 0.01 versus healthy-MSCs, ## p < 0.01 versus non-treated CKD-MSCs, $$ p < 0.01 versus pioglitazone-treated CKD-MSCs pretreated with si-PRNP.